Earnings Call Intelligence Subscribe
Home › Call Sheets › BSX › Q2'26
Call sheet · Q2'26

Boston Scientific (BSX)

Q2'26 earnings call · held July 29, 2026 · compared with the Q1'26 call · management-credibility review
5/12
Disclosure score
2 high, 6 medium, 1 low flags
Financial quality
Bottom line
The market will focus on the guidance cut, but the real story is the **$1.5 bn MIRAS/TAVR investment and the Penumbra acquisition** - a >$2 bn pipeline that could fuel 6‑8% organic growth and offset the EP/Watchman headwinds. The headline slowdown is driven by **U.S. EP market‑share loss (PFA now ~80% of AF market) and the clinical‑evidence shift that crippled standalone Watchman volumes**; those are the binding constraints on top‑line. Management’s quote, "Our IC business and ICBT broadly will be our strongest growth driver," is the only concrete growth anchor. **My view changes if the Penumbra close is delayed or the MIRAS TAVR option fails to meet milestones - both would remove >$500 m of near‑term cash outflow and erode the cost‑saving runway.**

The 30-second version

  • Sleeper story: the $1.5 bn MIRAS/TAVR option and the pending Penumbra deal are the real growth engine the market is ignoring
  • Headline cut is really a “Watchman‑EP” story, not a “market‑wide” slowdown
  • Red flag: key forward‑looking metrics vanished and language shifted to “early days”

What changed this quarter

MetricQ1'26Q2'26Change
Revenue (reported)$5.203 bn (+11.6% YoY)$5.442 bn (+7.5% YoY)-4.1 ppt YoY growth deceleration
Organic revenue growth9.4% YoY7.0% YoY-2.4 ppt
Adjusted EPS$0.80 (+6% YoY)$0.86 (+15% YoY)+5 cents, +9 ppt YoY
Adjusted gross margin70.5% (‑100 bps YoY)70.3% (+80 bps YoY)+0.8 ppt YoY
Adjusted operating margin28.0% (+70 bps YoY)28.4% (+70 bps YoY)+0.4 ppt
GAAP operating margin (gap)21.2%21.6%+0.4 ppt
Adjusted tax rate11.7%10.4%-1.3 ppt (favorable)
Fully diluted shares outstanding1.495 bn1.475 bn-20 m shares (≈1.3% reduction)
Product liability charge (one‑time)N/A$75 mnew expense
IEPA tariff refunds (one‑time)N/A$80 mcash benefit

Accountability tracked

7 new promises made6 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BSX Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.